IRD Stock Forecast: Opus Genetics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$3.99
−2.21% on the day

The median 12-month analyst price target for Opus Genetics, Inc. is $14. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 39 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$385.7M
Ticker Nerd rank
39/ 100
Median analyst target
$14
Analysts covering
18
Revenue$755K−73.8% y/y
Operating income−$16.5M
Net income−$8.1M
Free cash flow−$11.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.3%
1M
−0.5%
YTD
+98.5%
1Y
+106.7%
From 52W high
−34.3%
From 52W low
+108.9%
$1.91
$6.07
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Opus Genetics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
39/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
95
Volatility
83
Value
62
Growth
52
Accruals
45
Revisions
29
Quality
22
Issuance
5

Momentum (95): The shares have been drifting up relative to others.

Issuance (5): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

IRD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IRD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Jan 26Apr 26Jul 26Oct 26IRDHigh $20Median $14Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says18 analysts
18
Buy
0
Hold
0
Sell
$8
Low
$14
Median
$20
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
11 Nov 2026HC Wainwright & Co.MaintainsBuy$8.00 → $14
11 Nov 2026RBC CapitalMaintainsOutperform$9.00 → $11
22 Oct 2026Chardan CapitalMaintainsBuy$16
16 Oct 2026CitizensReiteratesMarket Outperform$17
6 Oct 2026Jones TradingMaintainsBuy—
2 Oct 2026Chardan CapitalMaintainsBuy$16
10 Sept 2026WedbushMaintainsOutperform$10 → $13
9 Sept 2026BTIGReiteratesBuy$12
9 Sept 2026Chardan CapitalMaintainsBuy$13 → $16
9 Sept 2026HC Wainwright & Co.ReiteratesBuy$8.00
9 Sept 2026OppenheimerMaintainsOutperform$10 → $20
7 Aug 2026RBC CapitalMaintainsOutperform$10 → $9.00
29 July 2026TD CowenInitiatesBuy—
6 July 2026BTIGReiteratesBuy$12
6 July 2026Chardan CapitalMaintainsBuy$13
18 June 2026Chardan CapitalMaintainsBuy—
17 June 2026HC Wainwright & Co.ReiteratesBuy—
16 June 2026BTIGReiteratesBuy—
15 June 2026CitizensReiteratesMarket Outperform—
4 June 2026GuggenheimInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for IRD.

Market Radar

This page is one stock. Monday covers all of them.

IRD appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

IRD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Opus Genetics, Inc. returned +106.7% against +6.9% for the S&P 500, dividends included.

IRD vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Jan 26Apr 26Jul 26Oct 26IRDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IRD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
48.7×

Cheaper than 5% of US stocks

Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−58.5%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Opus Genetics, Inc. has a market value of $385.7M and an enterprise value of $332.6M.

  • Revenue in the twelve months to 30 June 2026: $9.9M. The latest quarter shrank 73.8% year on year.

  • Net income over the same four quarters: −$107.6M, a −1091.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$40.7M.

  • Opus Genetics, Inc. spent $149K on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 82.6M.

  • Opus Genetics, Inc. employs 27 people — $365K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

IRD and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IRDOpus Genetics, Inc.$385.7M39
AVTXAvalo Therapeutics, Inc.$390.9M29
CADLCandel Therapeutics, Inc.$395.4M43
RZLTRezolute, Inc.$375.1M42
TVGNTevogen, Inc.$405.2M17
PHATPhathom Pharmaceuticals, Inc.$364.9M79
OVIDOvid Therapeutics, Inc.$410.6M47

Take a look at IRD’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Opus Genetics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about IRD

What is the IRD stock price forecast for 2026-2027?

The median 12-month analyst price target for Opus Genetics, Inc. is $14, with estimates ranging from $8 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IRD stock a buy right now?

Of the 18 analysts covering Opus Genetics, Inc., 18 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Opus Genetics, Inc. 39 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IRD?

As at 21 Nov 2026, Opus Genetics, Inc. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (95 of 100).

Will IRD stock go up?

No one can know that. What the data says: the median 12-month target from 18 analysts is $14, and Ticker Nerd's factor model ranks Opus Genetics, Inc. 39 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IRD stock forecast for 2030?

No analyst covering Opus Genetics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IRD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $20 over the next 12 months.

How has IRD stock performed over the past year?

Opus Genetics, Inc. returned +106.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Opus Genetics, Inc. do?

Opus Genetics, Inc. Common Stock represents an equity interest in Opus Genetics, a clinical-stage biopharmaceutical company focused on ophthalmic therapies. The company develops gene therapies for inherited retinal diseases and additional small-molecule treatments for other eye disorders, including programs aimed at retinal degeneration, refractive conditions, and other vision-related diseases.

Company

About Opus Genetics, Inc.

Opus Genetics, Inc. Common Stock represents an equity interest in Opus Genetics, a clinical-stage biopharmaceutical company focused on ophthalmic therapies. The company develops gene therapies for inherited retinal diseases and additional small-molecule treatments for other eye disorders, including programs aimed at retinal degeneration, refractive conditions, and other vision-related diseases. Its current pipeline includes investigational candidates such as OPGx-LCA5 and OPGx-BEST1, along with other ophthalmology-focused programs targeting specific genetic retinal conditions. Opus Genetics serves the broader vision-care market through research, development, and commercialization efforts centered on restoring or preserving sight in patients with unmet medical needs. The company is headquartered in Durham, North Carolina.

CEO Dr. George Magrath M.B.A., M.D., M.S. · 27 employees · United States · https://opusgtx.com